MedTrace Logo

Aripiprazole Oral Acceptability Trial

NCT00101569 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 59

Last updated 2013-11-08

No results posted yet for this study

Summary

The purpose of this trial is to study liquid aripiprazole in patients with stable schizophrenia.

Conditions

Interventions

DRUG

Aripiprazole

Tablets, Oral, 15 -30 mg, once daily, 2 weeks (days 1 -14).

DRUG

Aripiprazole

Oral Solution, Oral, 15-30 ml, once daily, 1 week (days 15 -21).

Sponsors & Collaborators

  • Otsuka America Pharmaceutical

    collaborator INDUSTRY

  • Otsuka Pharmaceutical Development & Commercialization, Inc.

    lead INDUSTRY

Principal Investigators

  • Bristol-Myers Squibb · Bristol-Myers Squibb

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-03-31
Primary Completion
2005-03-31
Completion
2005-03-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00101569 on ClinicalTrials.gov